Business

Experimental Lung Cancer Drug Shows Promising Results

Updated 2026-05-31 22:05 UTC 1 source Positive

A new lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, marking a significant breakthrough.

Coverage timeline — 1 article

CNBC

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

2026-05-31 12:00 UTC